15:40 , May 10, 2019 |  BC Extra  |  Clinical News

Polyphor valuation cut in half on halted Phase IIIs of antibiotic murepavadin

Polyphor lost CHF12.27 (48%) to CHF13.38 on Friday after announcing late Thursday that it suspended enrollment in a pair of Phase III trials of pneumonia antibiotic murepavadin (POL7080) after observing a higher-than-expected incidence of acute...
23:57 , Apr 18, 2019 |  BC Extra  |  Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

While Wednesday's announcement that Yale researchers restored cell function in postmortem pig brains sheds no light on the feasibility of reviving consciousness, it does suggest new opportunities for stroke treatments, disease models and validation of...
11:05 , Apr 3, 2019 |  BC Extra  |  Financial News

Bigger bites, more digital health for HealthQuest's new $440M fund

With a new $440 million venture fund nearly double the size of its predecessor, HealthQuest Capital plans to take bigger stakes in its portfolio companies and grow its footprint in digital health. While the Bay...
17:16 , Mar 20, 2019 |  BC Extra  |  Financial News

Flagship closes second Special Opportunities fund at $824M

To help the firm support companies originating from its Flagship Labs incubator, Flagship Pioneering announced Wednesday the close of its Special Opportunities Fund II at $824 million. Investing in the fund are undisclosed LPs as...
14:36 , Mar 5, 2019 |  BC Extra  |  Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
23:41 , Jan 25, 2019 |  BioCentury  |  Finance

Kurma’s Munich move

Kurma Partners has opened a Munich office to spin out German academic science into biotechs in a bid to apply its company creation model to bridge the country’s venture capital gap for translating compelling research....
22:12 , Dec 14, 2018 |  BioCentury  |  Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation In vitro , cell culture and mouse studies identified an OGG1 inhibitor that could help treat pulmonary inflammation. Screening of a small molecule library via an in vitro activity assay, followed by optimization...
22:57 , Nov 30, 2018 |  BioCentury  |  Finance

Global Dimensions

6 Dimensions Capital has invested in at least nine U.S. biotechs this year out of its inaugural U.S. dollar fund, and the pace is expected to continue. Those investments have caught the eye of the...